This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Real Story: Less Is Not More

With CNBC bringing on a plethora of crisis consultants in the aftermath of the vice president's recent public relations disaster, you'd think management of publicly traded companies might have taken a few notes. But American Pharmaceutical Partners (APPX) opted to keep investors guessing on pertinent information regarding fourth-quarter results and, more importantly, expectations for 2006. Management has already come under fire for keeping tightlipped about its pending acquisition of American BioScience, announced in November.

To review, American Pharma is purchasing American BioScience in an all-stock transaction. American Pharma founder and majority owner Dr. Patrick Soon-Shiong owns more than 85% of American BioScience and could see a windfall of more than $2 billion if the deal is consummated.

Details on how the purchase price was decided were not revealed until Feb. 13 in a document filed with the Securities and Exchange Commission. But the merger was reviewed by a special committee of purportedly independent board members -- board members who were paid six-figure sums to seemingly rubber-stamp the deal. A full recap is available here .

On Friday, American Pharma released its fourth-quarter results. The company earned 38 cents per share (excluding one-time items), beating the consensus estimate of 35 cents. Revenue, however, came in a little light at $144.83 million vs. expectations of $151.5 million.

On the conference call, American Pharma symbolically sprayed buckshot in the face of already anxious investors by refusing to give guidance for 2006. The company also failed to assuage concerns of channel-stuffing prior to a year-end price increase for cancer fighter Abraxane.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs